SCHEDULE 13D/A: BlackRock Health Sciences Term Trust to Repurchase 40% of Shares in Settlement with Activist Investor Saba Capital

BlackRock Health Sciences Term Trust (BMEZ) has agreed to a cash tender offer to repurchase 40% of its outstanding common shares at 99.5% of net asset value, settling a dispute with activist investor Saba Capital Management, L.P., which will tender its shares and abide by a three-year standstill agreement.

Summary

• BlackRock Health Sciences Term Trust (BMEZ) will conduct a cash tender offer to repurchase 40% of its outstanding common shares.
• The tender offer price will be 99.5% of the Fund's net asset value (NAV) per share.
• The tender offer is expected to commence on March 21, 2025, and will expire on the 20th business day after commencement, with payment within 7 business days thereafter.
• Saba Capital Management, L.P. (Saba Capital), which beneficially owns 20,750,913 common shares (19.98% of the class), has agreed to tender all its shares in the offer.
• Saba Capital paid approximately $310,584,392 to acquire the reported common shares.
• In exchange, Saba Capital has withdrawn its shareholder proposal submitted on October 9, 2024, and agreed to customary standstill provisions until the earliest of the Fund's 2027 annual meeting or August 31, 2027, or August 18, 2025, if payment for tendered shares is not made.
• The Fund has also cancelled its previously announced tender offer for the quarterly measurement period ended December 31, 2024, and terminated its discount management program.

Sentiment

Score: 7

Explanation: The agreement resolves a significant activist challenge, providing a clear path for shareholder liquidity at a favorable price (near NAV). While some previous shareholder programs are cancelled, the overall resolution is positive for stability and addressing discount concerns, though the proration risk for the tender offer is a minor negative.

Positives

• The tender offer provides liquidity to shareholders at a price close to Net Asset Value (99.5% of NAV), which is beneficial for shareholders seeking an exit.
• The agreement resolves a potential activist dispute with Saba Capital, leading to stability in corporate governance.
• Saba Capital's commitment to tender its shares and abide by standstill provisions reduces immediate pressure on management and the Board.
• The withdrawal of Saba Capital's shareholder proposal avoids a potentially contentious proxy fight.

Negatives

• The tender offer is for 40% of outstanding shares, meaning not all shareholders will be able to tender their full positions if the offer is oversubscribed, leading to proration.
• The cancellation of the previously announced quarterly tender offer and termination of the discount management program might disappoint some shareholders who relied on those mechanisms for liquidity or discount narrowing.
• The standstill agreement restricts Saba Capital's ability to engage in certain shareholder activism, which some investors might view as limiting potential future governance improvements.

Risks

• The Fund's obligation to conduct the Tender Offer is subject to conditions, including not resulting in delisting from the NYSE or impairing the Fund's status as a regulated investment company (RIC), which could lead to delays or discontinuation.
• Legal or regulatory actions challenging the Tender Offer, or market disruptions (e.g., suspension of trading, banking moratorium), could delay or prevent the Tender Offer.
• Failure of Saba Capital to withdraw its shareholder proposal or submitting new ones could also prevent the Tender Offer.
• The agreement does not restrict Saba Capital from actions related to other funds advised by BlackRock or their respective trustees/directors, or from participating in ongoing ECAT/MUI litigation, which could still pose reputational or legal risks to BlackRock.

Future Outlook

The document outlines a clear path for a significant share repurchase program by BlackRock Health Sciences Term Trust, aiming to provide liquidity to shareholders at a price close to NAV. It also establishes a multi-year standstill agreement with a major activist investor, Saba Capital, which is expected to bring stability to the Fund's governance through the 2027 proxy season. The Fund commits to not issuing new shares or undertaking major corporate restructuring (like redomiciliation or merger) before the tender offer payment date.

Management Comments

• "BlackRock Advisors, LLC ('BlackRock') announced today that the Board of Trustees of BlackRock Health Sciences Term Trust (NYSE: BMEZ) has approved a tender offer to repurchase 40% of BMEZ's outstanding shares, in each case at a price per share equal to 99.5% of the applicable Fund's net asset value per common share determined following the expiration of the tender offer."
• "In connection with the approval of the applicable Tender Offer, each Board has approved (i) the cancellation of the applicable Fund's tender offer for the quarterly measurement period ended December 31, 2024, which was announced on January 2, 2025, and (ii) the termination of the applicable Fund's previously announced discount management program, effective immediately."
• "Saba Capital Management, L.P. (together with certain of its affiliates, 'Saba') today announced that it has entered into standstill agreements (the 'Agreements') with BlackRock Advisors, LLC, which is the investment advisor of the BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) and the BlackRock Health Sciences Term Trust (NYSE: BMEZ) (the 'Funds'), following constructive negotiations."

Industry Context

This agreement reflects a common trend in the closed-end fund industry where activist investors, like Saba Capital, target funds trading at a discount to their Net Asset Value (NAV) to push for liquidity events such as tender offers or open-ending. Such settlements aim to narrow the discount and provide an exit for shareholders, often in exchange for a standstill agreement from the activist. The mention of BlackRock Innovation and Growth Term Trust (BIGZ) undergoing a similar process suggests a broader strategy by BlackRock to address activist pressure across its closed-end fund lineup.

Comparison to Industry Standards

• The tender offer for 40% of shares at 99.5% of NAV is a significant liquidity event, often sought by activist investors in closed-end funds that trade at a discount. This is a relatively high percentage and a tight discount to NAV for such an offer.
• The agreement with Saba Capital Management, L.P. is consistent with similar settlements seen in the closed-end fund space, where activist funds like Saba (known for targeting discounts) negotiate tender offers or other discount-narrowing mechanisms in exchange for standstill provisions.
• The simultaneous announcement of a similar tender offer for BlackRock Innovation and Growth Term Trust (BIGZ) (50% of shares at 99.5% of NAV) indicates a consistent approach by BlackRock across its closed-end fund complex to address shareholder value concerns and activist pressure.

Corporate Governance

Legal Proceedings

• The agreement explicitly mentions ongoing or future litigation between Saba and BlackRock ESG Capital Allocation Term Trust (ECAT) and its trustees ('ECAT Litigation').
• It also mentions potential ongoing or future litigation involving ECAT and BlackRock Municipal Income Fund, Inc. (MUI) and their respective trustees/directors related to the proceedings captioned FS Credit Opportunities Corp. v. Saba Capital Master Fund, Ltd., et al, No. 24-345 (U.S. Supreme Court) ('ECAT/MUI Litigation').

Stakeholder Impact

• Shareholders: Shareholders will have an opportunity to tender up to 40% of their shares at a price close to NAV, providing liquidity. However, the offer is subject to proration if oversubscribed, and previous discount management programs are terminated. The resolution of the activist dispute may lead to more stable share performance.
• Management/Board: The agreement provides a period of stability and reduced activist pressure, allowing management to focus on the Fund's operations without immediate proxy contest threats.
• Saba Capital: Saba Capital achieves a significant liquidity event for a substantial portion of its investment at a favorable price, while agreeing to a standstill.

Next Steps

• BlackRock Health Sciences Term Trust (BMEZ) to commence a cash tender offer on March 21, 2025.
• Saba Capital to tender all its beneficially owned shares in the Tender Offer.
• Saba Capital to abide by standstill provisions until the earliest of the Fund's 2027 annual meeting, August 31, 2027, or August 18, 2025 (if payment is delayed).
• Saba Capital to vote its shares in accordance with the Board's recommendations during the standstill period.
• Saba Capital to file an amendment to its Schedule 13D with the SEC.
• Fund to issue press release on January 21, 2025.
• Saba to issue press release on January 21, 2025.

Key Dates

Recommendation

Keywords

BlackRock Health Sciences Term Trust, BMEZ, Saba Capital Management, Tender Offer, Standstill Agreement, Closed-End Fund, Activist Investor, Share Repurchase, Net Asset Value, SEC Filing, Schedule 13D, Corporate Governance, Investment Management